NIAB

CN Bio PhysioMimix Organ-on-a-Chip Data Supports Inipharm’s INI-822 for Metabolic Liver Disease Treatment Now in Clinical Testing

Retrieved on: 
Monday, December 4, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Molecule, OOC, Research, DSM-IV codes, Non-alcoholic fatty liver disease, Prevalence, MPS, Hepatology, Patient, Therapy, Drug discovery, NIAB, HSD17B13, NASH, Pharmaceutical industry

The use of in vitro OOC for early evidence of efficacy for INI-822 demonstrates the transformative potential of these models to provide human-relevant data within preclinical programmes.

Key Points: 
  • The use of in vitro OOC for early evidence of efficacy for INI-822 demonstrates the transformative potential of these models to provide human-relevant data within preclinical programmes.
  • Loss-of-function variants of this gene are known to be associated with reduced incidence risk and severity of multiple liver diseases.
  • As part of the recent regulatory submission, CN Bio’s Contract Research Services team utilised the Company’s PhysioMimix OOC Systems and NASH ‘in-a-box' (NIAB) kit to generate critical data to determine compound efficacy.
  • For more information, visit: https://cn-bio.com/
    Inipharm Initiates Dosing in Phase 1 Study of Its Small Molecule Inhibitor of HSD17B13: https://www.businesswire.com/news/home/20231130655005/en/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20231204544807/en/

CN Bio Introduces PhysioMimix NASH ‘in-a-box’ Reagent Kit

Retrieved on: 
Tuesday, April 26, 2022
Biotechnology, Medical Devices, Health, Pharmaceutical, Clinical Trials, NIAB, CEO, Adoption, ISCB Senior Scientist Award, World Community Grid, Research, NASH, Fatty liver disease, Drug discovery, Organic acid, Inflammation, MPS, Hepatocyte, Laboratory, NAFLD, OOC, CN, Non-alcoholic fatty liver disease, Prevalence, Disease, Liver, Therapy, Kupffer cell, Pharmaceutical industry, Snow

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today introduced its PhysioMimixin-a-box reagent kit for Non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD).

Key Points: 
  • CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today introduced its PhysioMimixin-a-box reagent kit for Non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD).
  • Previously only accessible via its contract research services, CN Bios best-in-class NASH in vitro model supports the urgent development of therapeutics to treat this emerging global healthcare priority.
  • In conjunction with CN Bios PhysioMimix MPS, the NASH-in-a-box (NIAB) kit provides researchers with in-house capabilities to gain physiologically relevant insights into the mechanism of disease, human drug efficacy and safety toxicology.
  • Dr David Hughes, CEO, CN Bio, said: NASH-in-a-box enables CN Bio to expand our market reach from those who prefer to outsource their testing to our laboratories, to those who would rather develop in house capabilities.